The Draft Executive Order on Drug prices
Attached here is the draft Trump Executive Order, titled “REDUCING THE COST OF MEDICAL PRODUCTS AND ENHANCING AMERICAN BIOMEDICAL INNOVATION,” as leaked by Politico today.
Author: James Love
Comment on proposed Trump Executive Order on drug prices
I wrote an 1800 word comment on the proposed Trump Executive Order on drug prices in medium, here. The bulk of the comment focused on the first of the “principles” and “talking points” reported by Emily Kopp in Kaiser Health News.
KEI comments to USTR on the negotiating objectives for the modernization of NAFTA
USTR has a request for comments on negotiating objectives for the moderation of NAFTA, docket USTR-2017-0006, and will hold a public hearing on June 27, 2017. KEI filed a set of comments and a request to testify, available here.
KEI’s comments cover an eclectic set of issues.
Apple obtains compulsory license on patents owned by WARF, by District Court Judge in Wisconsin
On June 6, 2017, Judge William Martin Conley, a United States District Judge of the United States District Court for the Western District of Wisconsin, issued a compulsory license allowing Apple Computers to use a patent it had infringed, owned by the Wisconsin Alumni Research Foundation (WARF), in return for an ongoing royally. Apple was found to infringe U.S. Patent No. 5,781,752, titled “Table based data speculation circuit for parallel processing computer. WARF asked for a permanent injunction to prevent future infringement. Continue Reading
Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs
Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs
KEI Briefing Note 2017:2. James Love. Revised 31 May 2017.
Groups ask Army to reconsider decision that would allow French firm to charge U.S. anything it wants on federally-funded vaccine
23 May 2017
Groups ask Army to reconsider decision that would allow French firm to charge the US anything it wants on a federally funded Zika vaccine
CONTACT: Zack Struver, zack.struver@keionline.org, +1 (914) 582-1428
Andrew Goldman, andrew.goldman@keionline.org
James Love, james.love@keionline.org, +1 (202) 361-3040
KEI submission to OECD consultation on “Sustainable access to innovative therapies”
This was the KEI submission to the OECD consultation on “Sustainable access to innovative therapies,” which involved four questions posed by OECD on access to medicines.
Question 1: Reflecting on the last 5-10 years, what do you think have been the major changes affecting access to medicines?
Continue Reading
Democrats in House and Senate introduce new drug pricing bill
Dr. Elias Zerhouni defends Sanofi/Army proposed license on Zika patents, and KEI responds
On March 21, 2017, the New York Times published a letter signed by Dr. Elias Zerhouni, defending the proposed Sanofi monopoly on the US Army patents to the Zika virus. The letter is available from the NYT from the following link, and also reprinted here, followed by commentary.
https://www.nytimes.com/2017/03/21/opinion/developing-a-zika-vaccine.html
To the Editor:
Re “Trump Should Avoid a Bad Zika Deal” (Op-Ed, March 11):
Maryland House of Delegates passes bill on prescription drug price gouging by vote of 137 to 4
On March 20, 2017, the Maryland House of Delegates approved a prescription drug price gouging bill by a vote of 137-4. A copy of the bill, as it passed the House, is attached.
This is a March 20, 2017 Report by Erin Cox, published in the Baltimore Sun:
Maryland’s attorney general could sue drug companies for price gouging under a bill approved by the House of Delegates Monday.